Premium
Biopharmaceutical characteristics of a new propranolol/ hydrochlorothiazide tablet combination
Author(s) -
Kraml M.,
Dubuc J.,
Dvornik D.,
PattersonKreuscherv S.,
Perdue H.,
Lee T. Y.,
Mullane J.
Publication year - 1982
Publication title -
biopharmaceutics and drug disposition
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.419
H-Index - 58
eISSN - 1099-081X
pISSN - 0142-2782
DOI - 10.1002/bdd.2510030108
Subject(s) - hydrochlorothiazide , bioavailability , propranolol , cmax , pharmacokinetics , pharmacology , diuretic , biopharmaceutical , dosage form , chemistry , medicine , endocrinology , blood pressure , biology , genetics
Experiments have been carried out in dogs and man to determine the effect of hydrochlorothiazide (HCT) on the pharmacokinetics of propranlol and to evaluate the bioavailability of two dosage forms containing both propranolol and HCT (40/25 and 80/25 mg, respectively). In adult male beagles, 50 mg of HCT had no apparent effect on AUC, C max , T max , and T 1/2 of propranolol administered concurrently. In man, INDERIDE® (40/25 mg) and INDERIDE® (80/25 mg) were shown to be similar in bioavailability to the reference formulations, i.e. the same amount of drugs administered as the separate tablets of INDERAL® plus HYDRODIURIL®.